Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis -

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Information type: Other primary research
Source: Annals of Rheumatic Diseases
Specialities: Musculo-skeletal disorders
Summary
This pooled safety analysis (n=2865) reported that SC golimumab safety up to 3 years remained consistent with that of other TNF antagonists. Golimumab 100 mg showed numerically higher incidences of serious infections, demyelinating events and lymphoma than 50 mg.
UKMi comment
The most common adverse events reported during the studies (defined as occurring in >5% of patients in any patient group up to week 160) included upper respiratory tract infection, nasopharyngitis, nausea, cough, headache, back pain, bronchitis, sinusitis, hypertension, diarrhoea, injection-site erythema, urinary tract infection, fatigue, rash, pharyngitis, influenza, and ALT/AST increased.
Related links: